NCT06761677 2026-02-05A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell LymphomaSymBio PharmaceuticalsPhase 1/2 Suspended43 enrolled